1. In Vivo
  2. >>COVID-19

Coronavirus-Driven Regulatory Changes Put Telehealth On The Map

Experts Predict Telehealth Will Become The New Normal

 
• By Marion Webb

Adoption of telehealth services has skyrocketed during the coronavirus outbreak and US experts are expecting the trend to continue post-pandemic, fundamentally transforming health care.

Global strategy solution concept - earth jigsaw puzzle

The COVID-19 pandemic has pushed telehealth services to the forefront of health care and many expect its widespread use to continue far beyond the current crisis.

As of late-April, more than 3 million cases of coronavirus had been detected worldwide and the global death toll had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

 
• By Eleanor Malone

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

 
• By Bowman Cox

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

 
• By Lucie Ellis-Taitt

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

 
• By Andrew McConaghie

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.